KITE Stock Forecast – Quick Win: 26.92% in 1 Month

KITE Stock Forecast

On October 2nd of 2015, The I Know First algorithm gave signal of 17.4 for the ticker KITE (Kite Pharma Inc), which had a predictability indicator of 0.47. In accordance with the algorithm’s prediction, KITE spiked 26.92% in 1 month from October 2nd to November 2nd.

KITE Stock Forecast

Kite Pharma, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company does this using its engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer.

During this period of time the company announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) embraced positive opinions recommending KTE-C19 for designation as an orphan medicinal product for the treatment of ALL, CLL/SLL, and FL. KTE-C19 is an investigational therapy in which a patient’s T cells are genetically modified to express a chimeric antigen receptor (CAR) designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias.

Later during the month Kite started a new cancer treatment that in the future could make huge progress in erasing this horrible disease. Their treatment of non-Hodgkin’s lymphoma reprograms a patient’s T-cells the kind that are supposed to fight disease to seek and destroy only abnormal, cancerous lymph cells, not the healthy ones crucial for human life. For this to work first they need to extract blood from the patient, modify the cells and then re-inject them into the patient.

Although it could be a year or longer before the FDA approves its treatment for non-Hodgkin’s lymphoma, the clinical results are so  favorable that Kite has started to build a 44,000-square-foot facility that would become its cancer-fighting nerve center.

In addition to non-Hodgkin’s lymphoma, Kite plans to use T-cell modification to treat leukemia and many other types of cancer.

Business Disclosure: I Know First Research is the analytic branch of I Know First, a financial startup company that specializes in quantitatively predicting the stock market. We did not receive compensation for this article, and we have no business relationship with any company whose stock is mentioned in this article. Read More From I Know First Research :

  • The Walt Disney Company: Beyond ESPN And Star Wars (View)
  • Now Boarding: American Airlines (View)
  • Visa Share Price is on the Rise (View)
  • For long Term Growth, Look No Further Than Gilead Sciences  (View)
  • Investing in World’s Greatest Killers Gives Amgen Enormous Upside potential (View)